Nicolas Guedeney

Dr. Nicolas Guedeney

ISCR UMR 6226, Corint team, University of Rennes, Rennes, Bretagne, France
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Drug Discovery Today
Verified
Journal Article
Closed access
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
MCMarie Cornu
Marie Cornu
FSFlorian Schwalen
Florian Schwalen
CKCharline KIEFFER
Charline KIEFFER
AVAnne Sophie Voisin-Chiret
Anne Sophie Voisin-Chiret

5 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
LDLaurent Devel
Laurent Devel
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
SBSarah Bregant
Sarah Bregant
ACAnimesh Chowdhury
Animesh Chowdhury
MJMickael Jean
Mickael Jean
Patrick LegembrePatrick Legembre
Patrick Legembre
CD95L (also known as FasL or CD178) is a member of the tumor necrosis family (TNF) superfamily. Although this transmembrane ligand has been mainly considered as a potent apoptotic inducer in CD95 (Fas)-expressing cells, more recent studies pointed out its role in the implementation of non-apoptotic signals. Accordingly, this ligand has been associated with the aggravation of inflammation in different auto-immune disorders and in the metastatic occurrence in different cancers. Although it remains to decipher all key factors involved in the ambivalent role of this ligand, accumulating clues suggest that while the membrane bound CD95L triggers apoptosis, its soluble counterpart generated by metalloprotease-driven cleavage is responsible for its non-apoptotic functions. Nonetheless, the metalloproteases (MMPs and ADAMs) involved in the CD95L shedding, the cleavage sites and the different stoichiometries and functions of the soluble CD95L remain to be elucidated. To better understand how soluble CD95L triggers signaling pathways from apoptosis to inflammation or cell migration, we propose herein to summarize the different metalloproteases that have been described to be able to shed CD95L, their cleavage sites and the biological functions associated with the released ligands. Based on these new findings, the development of CD95/CD95L-targeting therapeutics is also discussed.

10 September 2018 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
JDJade Dussart-Gautheret
Jade Dussart-Gautheret
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
JDJulia DESCHAMP
Julia DESCHAMP
MMMaelle Monteil
Maelle Monteil
OGOlivier Gager
Olivier Gager
Marc LecouveyMarc Lecouvey
Marc Lecouvey
A practical generalisable procedure to synthesize hydroxymethylene H-bisphosphinates has been optimised. Unlike previous reports, numerous alkyl (including an alendronate bisphosphinate analogue) or (hetero)aryl compounds were rapidly obtained in satisfactory to excellent yields. A side product could have been identified as a phosphino-phosphonate isomer and plausible mechanistic pathways are proposed here. Moreover to check the literature data, a pKa value study was also performed.

10 December 2018 in Phosphorus, Sulfur, and Silicon and the Related Elements
Verified
Journal Article
Closed access
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
JDJade Dussart-Gautheret
Jade Dussart-Gautheret
JDJulia DESCHAMP
Julia DESCHAMP
MOMouna Ouechtati
Mouna Ouechtati
EMEvelyne Migianu-Griffoni
Evelyne Migianu-Griffoni
Marc LecouveyMarc Lecouvey
Marc Lecouvey
A convenient and generalizable procedure has been optimized to access to 1-hydroxymethylene-1,1-bisphosphinate compounds. Several alkyl, including an alendronate bisphosphinate analog, and (hetero)aryl compounds were rapidly obtained in satisfying to excellent yields. A side product could be identified as a phosphino-phosphonate isomer and plausible mechanistic pathways are discussed here.

19 December 2023 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
JDJulia DESCHAMP
Julia DESCHAMP
TLThibaut Legigan
Thibaut Legigan
MMMaëlle Monteil
Maëlle Monteil
EMEvelyne Migianu-Griffoni
Evelyne Migianu-Griffoni
MLMarc Lecouvey
Marc Lecouvey
1-Hydroxymethylene-1,1-bisphosphonate (HMBP) derivatives are widely used for the treatment of bone disorders and for bone imagery. Through their high affinity for bone matrix hydroxyapatite, they have shown promising development as powerful bone vectors for many bioactive compounds. To improve the toolbox of conjugatable bisphosphonates, we reported here a convenient synthesis of alendronate derivatives bearing tunable functions on their side chain. The developed straightforward synthetic strategy provides substituted 1-aminoalkyl-1-hydroxymethylene-1,1-bisphosphonates (N-HMBPs) for conjugation strategies.

30 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MFMarc Farag
Marc Farag
CKCharline KIEFFER
Charline KIEFFER
Nicolas GuedeneyNicolas Guedeney
Nicolas Guedeney
AVAnne Sophie Voisin-Chiret
Anne Sophie Voisin-Chiret
JSJana Sopková-de Oliveira Santos
Jana Sopková-de Oliveira Santos
X-linked inhibitor of apoptosis protein (XIAP) exercises its biological function by locking up and inhibiting essential caspase-3, -7 and -9 toward apoptosis execution. It is overexpressed in multiple human cancers, and it plays an important role in cancer cells’ death skipping. Inhibition of XIAP-BIR3 domain and caspase-9 interaction was raised as a promising strategy to restore apoptosis in malignancy treatment. However, XIAP-BIR3 antagonists also inhibit cIAP1-2 BIR3 domains, leading to serious side effects. In this study, we worked on a theoretical model that allowed us to design and optimize selective synthetic XIAP-BIR3 antagonists. Firstly, we assessed various MM-PBSA strategies to predict the XIAP-BIR3 binding affinities of synthetic ligands. Molecular dynamics simulations using hydrogen mass repartition as an additional parametrization with and without entropic term computed by the interaction entropy approach produced the best correlations. These simulations were then exploited to generate 3D pharmacophores. Following an optimization with a training dataset, five features were enough to model XIAP-BIR3 synthetic ligands binding to two hydrogen bond donors, one hydrogen bond acceptor and two hydrophobic groups. The correlation between pharmacophoric features and computed MM-PBSA free energy revealed nine residues as crucial for synthetic ligand binding: Thr308, Glu314, Trp323, Leu307, Asp309, Trp310, Gly306, Gln319 and Lys297. Ultimately, and three of them seemed interesting to use to improve XIAP-BR3 versus cIAP-BIR3 selectivity: Lys297, Thr308 and Asp309.